Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy.

ABSTRACT:

Background

Predictive preclinical models play an important role in the assessment of new treatment strategies and as avatar models for personalised medicine; however, reliable and timely model generation is challenging. We investigated the feasibility of establishing patient-derived xenograft (PDX) models of high-risk neuroblastoma from a range of tumour-bearing patient materials and assessed approaches to improve engraftment efficiency.

Methods

PDX model development was attempted in NSG mice by using tumour materials from 12 patients, including primary and metastatic solid tumour samples, bone marrow, pleural fluid and residual cells from cytogenetic analysis. Subcutaneous, intramuscular and orthotopic engraftment were directly compared for three patients.

Results

PD

SUBMITTER: Kamili A 

PROVIDER: S-EPMC7054410 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature